Dompridone is commonly used for the treatment of vomiting and other GIT disorders. Counseling of drugs is one of the important responsibility of pharmacist. This article covers some useful parameters that must be communicated to the patients before dispensing the drugs to them. It will ultimately improves the quality of life of patients.
Counseling for Pharmacokinetics:
It is not always required to discuss pharmacokinetic parameter with patients but if patient want to know information about drug like
- How much time the drug will take to show its effects?
- What will be the response of my body when I will take this drug?
- How much time the drug require to remove from my body?
- What are the possible routes of excretion of the drug?
To answer such questions asked by patients, it is the duty of pharmacist to have information about pharmacokinetic parameters of drug. Following information can be given by pharmacist if he/she ask above mentioned questions.
- Bioavailability High
- Protein binding 91–93%
- Metabolism Hepatic and intestinal (first-pass)
- Half-life 7 hours
- Excretion Breast milk, renal
Counseling for Indication:
Domperidone is routinely prescribed to treat the stomach disorders such as nausea and vomiting, dyspepsia and gastro-oesophageal reflux. The pharmacist should validate the condition of the patient before dispensing the drug. If the patient is not suffering any above mentioned abnormalities then contact the physician to verify the use of medicine in that patient.
Counseling for Dose:
Every drug has a specific dose used to get the desired therapeutic effect. This dose can be changed depending upon the age of the patient and severity of disease. The pharmacist should verify the dose of domperidone by considering the condition of patient including his/her medical history. The dose of domperidone is given as below;
For Oral Route:
- Adult and child body-weight over 35 kg, 10–20 mg 3–4 times daily; max. 80 mg daily;
- Child’s body-weight up to 35 kg (nausea and vomiting only), 250–500 micrograms/kg 3-4 times daily; max. 2.4 mg/kg daily.
- Adult and child body-weight over 35 kg, 60 mg twice daily; child 15–35 kg (nausea and vomiting only), 30 mg twice daily;
- Child body-weight under 15 kg, not recommended
Counseling for Side effects:
The pharmacist should discuss regarding all the possible side effects associated with domperidone. He/she must discuss with the patients that side effects do not mean that you will suffer all these all but only very few patients suffer such side effects. Common side effects of this drug include her headache, dizziness, dry mouth, nervousness, flushing, very rarely extrapyramidal effects and rashes Consult your physician if you have any of the above adverse effects.
Counseling for Drug interaction:
The pharmacist should check rationality of drugs like drug- drug interactions and if there is any drug which is interfering the therapeutic effects of domperidone then counsel the patients that do not use such drugs concomitantly. Following are few drugs that can interact with domperidone include furazolidone, phenelzine, selegiline, tranylcypromine.
Counseling for Food Interaction:
Instruct the patient that domperidone can be taken 30 minutes before meals and at bedtime. counsel the patient that do not use caffeine and alcohol when taking domperidone.
Counseling for Pregnancy:
Domperisone has been assigned pregnancy category C. So strong precautions are needed while using this drug in pregnant and nursing women.
Counseling for Overdose:
Counsel the patients that If you have taken overdose of domperidone then call emergency. Symptoms of overdose may include drowsiness, dizziness, confusion, twitching, muscle rigidity, and irregular heartbeat..
Counseling for Missed Dose:
Counsel the patient that if you have missed a dose take it as soon as you remember. If it is near the time of the next dose, skip the missed dose.
Counseling for Storage:
Tell the patient that this medication can be stored at room temperature and avoid it exposure to heat and light.
- Motinorm Costi
- Tatro DS, Borgsdorf LR. A to z drug facts. Facts & Comparisons, 2003.
- Committee JF, Britain RPSoG. British National Formulary (BNF) 64. Pharmaceutical Press, 2012.
- Knoben JE, Anderson PO, Watanabe AS. Handbook of clinical drug data. Drug Intelligence Publications Hamilton, IL, 1988.
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.None found.